Percutaneous Ventricular Assist Devices: New Deus Ex Machina?

Table 1

Early clinical outcome in (A) patients with cardiogenic shock and treated with surgical or percutaneous ventricular assist device (s- or pVAD) and (B) in patients after preventive pVAD implantation for high-risk percutaneous coronary intervention (PCI).

	Device	N of patients	30-day survival
A. (Cardiogenic shock)	sVAD^a	157	92 (59%)
	pVAD^b	102	65 (64%)
B. (High-risk PCI)	pVAD TH^c	113	94 (83%)
	pVAD IP^d	152	59 (78%)

TH means TandemHeart, IP is for Impella Recover 2.5 LP; (a) pooled data from 11 trials [17, 28–37], (b) pooled data from 11 trials [5–7, 15, 19, 38–43], (c) pooled data from 11 trials [44–54], and (d) pooled data from 10 trials [55–64].